Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MASP2 | O00187 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | NOS1 | P29475 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 2/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.45 |
| ▸ | HTR3B | O95264 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.45 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16275249 | 0.82 | NOS1 (0.48) | PLAUCYP3A4GFERNOS1F2 | |
| SCHEMBL1520205 | 0.80 | CA2 (0.60) | ALDH1A1TDP1HTR3EHTR3BHTR3A | |
| SCHEMBL2700841 | 0.80 | LOXL2 (0.60) | PLAUNOS1F2PRSS1PRSS3 | |
| Hydrochloric Acid SCHEMBL11144849 | 0.78 | CA2 (0.58) | ALDH1A1TDP1HTR3EHTR3BHTR3A | |
| SCHEMBL799651 | 0.78 | HTR3E (0.59) | TDP1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL20008634 | 0.78 | IDO1 (0.57) | PLAUALDH1A1NOS1F2PRSS1 | |
| Hydrochloric Acid SCHEMBL31314478 | 0.78 | LOXL2 (0.58) | PLAUNOS1LOXL2HTR3EHTR3B | |
| SCHEMBL183375 | 0.78 | IDO1 (0.57) | ALDH1A1TDP1NOS1APEX1LOXL2 | |
| SCHEMBL8842456 | 0.78 | IDO1 (0.57) | NOS1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL15149754 | 0.78 | HTR3E (0.44) | CYP3A4NOS1F2PRSS1PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937843-A1 | POLYMORPHISMS IN PONl ARE ASSOCIATED WITH ELEVATED ALANINE AMINOTRANSFERASE LEVELS AFTER XIMELAGATRAN OR TACRINE ADMINISTRATION | Astra Zeneca AB (SE) | 2008-07-02 | — | — | EP | disclosed |
| EP-1937841-A1 | POLYMORPHISMS IN MGST3 ARE ASSOCIATED WITH ELEVATED ALAT LEVELS AFTER XIMELAGATRAN TREATMENT | Astra Zeneca AB (SE) | 2008-07-02 | — | — | EP | disclosed |
| EP-1934371-A1 | SNPS IN THE APOB GENE AND SUSCEPTIBILITY TO INCREASED LEVELS OF ALAT FOLLOWING XIMELAGATRAN ADMINISTRATION | AstraZeneca AB (SE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007039722-A1 | POLYMORPHISMS IN PONl ARE ASSOCIATED WITH ELEVATED ALANINE AMINOTRANSFERASE LEVELS AFTER XIMELAGATRAN OR TACRINE ADMINISTRATION | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039718-A1 | POLYMORPHISMS IN MGST3 ARE ASSOCIATED WITH ELEVATED ALAT LEVELS AFTER XIMELAGATRAN TREATMENT | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039724-A1 | SNPS IN THE APOB GENE AND SUSCEPTIBILITY TO INCREASED LEVELS OF ALAT FOLLOWING XIMELAGATRAN ADMINISTRATION | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
| EP-1581255-A1 | AN ACQUEOUS PHARMACEUTICAL FORMULATION COMPRISING THE THROMBIN INHIBITOR MELAGATRAN AND USE OF THE FORMULATION IN THE MANUFACTURE OF A MEDICAMENT FOR USE BY NASAL ADMINISTRATION IN TREATING THROMBOEMBOLISM | AstraZeneca AB (SE) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004043486-A1 | AN ACQUEOUS PHARMACEUTICAL FORMULATION COMPRISING THE THROMBIN INHIBITOR MELAGATRAN AND USE OF THE FORMULATION IN THE MANUFACTURE OF A MEDICAMENT FOR USE BY NASAL ADMINISTRATION IN TREATING THROMBOEMBOLISM | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | WO | disclosed |
| US-6399658-B1 | REDUCING DRUG SIDE EFFECT | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2002-06-04 | — | — | US | disclosed |
| EP-1181048-A1 | A PHARMACEUTICAL FORMULATION CONTAINING AN INHIBITOR OF CARBOXYPEPTIDASE U AND A THROMBIN INHIBITOR | AstraZeneca AB (SE) | 2002-02-27 | — | — | EP | disclosed |
| EP-1015022-A1 | NEW IMPROVED FORMULATION FOR TREATMENT OF THROMBOEMBOLISM | AstraZeneca AB (SE) | 2000-07-05 | — | — | EP | disclosed |
| EP-1004304-A1 | COMPOSITION CONTAINING ASCORBIC ACID | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2000-05-31 | — | — | EP | disclosed |
| EP-0910573-A1 | NEW AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | Astra Aktiebolag (SE) | 1999-04-28 | — | — | EP | disclosed |
| WO-1998016252-A1 | NEW PHARMACEUTICAL PARENTERAL FORMULATION OF A THROMBIN INHIBITOR | ASTRA AKTIEBOLAG (SE) | 1998-04-23 | — | — | WO | disclosed |
| WO-1997046577-A1 | NEW AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRA AKTIEBOLAG (SE) | 1997-12-11 | — | — | WO | disclosed |
| WO-1997045138-A1 | NEW IMPROVED FORMULATION FOR TREATMENT OF THROMBOEMBOLISM | ASTRA AKTIEBOLAG (PUBL) (SE) | 1997-12-04 | — | — | WO | disclosed |
| WO-1997039770-A1 | NEW PHARMACEUTICAL FORMULATION OF A THROMBIN INHIBITOR FOR PARENTERAL USE | ASTRA AKTIEBOLAG (SE) | 1997-10-30 | — | — | WO | disclosed |
| EP-0799052-A1 | NEW ANTITHROMBOTIC FORMULATION, PROCESS FOR ITS MANUFACTURING, AND USE THEREOF | Astra Aktiebolag (SE) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996016671-A1 | NEW ANTITHROMBOTIC FORMULATION, PROCESS FOR ITS MANUFACTURING, AND USE THEREOF | ASTRA AKTIEBOLAG (SE) | 1996-06-06 | — | — | WO | disclosed |
| EP-0701568-A1 | NEW PEPTIDE DERIVATIVES | Astra Aktiebolag (SE) | 1996-03-20 | — | — | EP | disclosed |